Clinical Trial Update: Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluated the safety of CDNF delivered by brain infusion in patients with Parkinson's disease; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• CDNF (Cerebral Dopamine Neurotrophic Factor)

Snippet

Sponsor: Herantis Pharma Plc. | Conditions: Parkinson Disease, Movement Disorders | Phase 1, Phase 2 | Status: COMPLETED